LeonaBio financials
$3.51+22.30%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$19.5M | -$17.2M |
| Net income | -$19.0M | -$33.0M |
| Net margin | — | — |
| Diluted EPS | $-0.80 | $-1.73 |
| EBITDA | -$19.2M | -$17.0M |
| Operating cash flow | -$17.0M | -$20.9M |
| Free cash flow | -$17.0M | -$20.9M |
| Diluted shares | 23.7M | 19.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 |
|---|---|---|
| Cash & equivalents | $32.3M | $32.8M |
| Short-term investments | $18.7M | $34.8M |
| Total debt | $0.00 | $0.00 |
| Total assets | $56.9M | $71.6M |
| Total liabilities | $23.3M | $22.3M |
| Shareholders' equity | $33.6M | $49.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology